麻豆女优

Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • 麻豆女优 Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    • See All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • See All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • Emergency Room Boarding
  • Device Coverage by Medicare
  • Planned Parenthood Funding
  • Covid/Flu Combo Shot
  • RFK Jr. vs. Congress

TRENDING TOPICS:

  • Emergency Room Boarding
  • Device Coverage by Medicare
  • Planned Parenthood Funding
  • Covid/Flu Combo Shot
  • RFK Jr. vs. Congress

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Wednesday, Dec 16 2015

Full Issue

In Price-Gouging Investigation, Oversight Committee Calls For Generic-Drug Information From FDA

And Rep. Elijah Cummings, the ranking Democrat on the committee, is keeping the pressure on Valeant Pharmaceuticals. The Maryland lawmaker is asking for witnesses and documents from the CEO by Jan. 8.

Republicans on the House Oversight and Government Reform Committee sent a letter to the Food and Drug Administration on Tuesday requesting documents and information on the agency鈥檚 process for reviewing generic drug applications. The lawmakers called the request part of its investigation into high prescription drug prices. The letter, signed by Chairman Jason Chaffetz, R-Utah, and 12 other Republicans, said the committee questions the efficiency of the FDA鈥檚 approval process for generic drugs, which has slowed since the agency began collecting user fees from generic drugmakers in 2013. The committee suggested that if this process were faster, it could help spur competition and drive down prices. (Siddons, 12/15)

The ranking Democrat on the House Oversight and Government Reform Committee is turning up the heat on beleaguered Valeant Pharmaceuticals, as the committee continues investigating soaring drug prices. Cummings is now sending Valeant鈥檚 CEO a letter asking for the witnesses and documents by Jan. 8, ahead of a committee hearing. (12/16)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Today, April 27
  • Friday, April 24
  • Thursday, April 23
  • Wednesday, April 22
  • Tuesday, April 21
  • Monday, April 20
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Republish Our Content
  • Contact Us

Follow Us

  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

漏 2026 麻豆女优